Fintel reports that on October 8, 2024, HC Wainwright & Co. upgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) from ...

Fintel reports that on October 7, 2024, HC Wainwright & Co. initiated coverage of DiaMedica Therapeutics (NasdaqCM:DMAC) with ...

Cassava Sciences (SAVA) stock earns its only buy rating on Wall Street as H.C. Wainwright upgrades the stock citing the company's recent SEC settlement. Read more here.

Equities research analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Rhythm Pharmaceuticals in ...

Pharming Group (NASDAQ:PHAR – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 65.69% ...

RCI Hospitality Holdings (NASDAQ: RICK) has received a reaffirmed Buy rating and a $98.00 price target from H.C. Wainwright. The endorsement comes despite the company reporting a slight decrease ...

On Monday, H.C. Wainwright maintained a Buy rating on Entera Bio (NASDAQ:ENTX), with a price target of $10.00. The firm's stance comes after the recent American Society for Bone and Mineral ...

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report). The associated ...

Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Valneva (VALN – Research Report), reducing the price target to $20.00.

On Friday, Vincerx Pharma Inc (VINC) stock saw a modest uptick, ending the day at $0.39 which represents no change from the prior close of of $0.39. The stock opened at $0.39 and touched a low of ...